Seroquel® combined with Cognitive Remediation Therapy to conventional treatment in patients with schizophrenia - SCORE

Study identifier:D1449L00004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An open, randomised, parallel, three treatment groups, multicentre, phase IV study - in real life - to compare the change in social outcome of quetiapine fumarate (Seroquel®) combined with Cognitive Remediation Therapy to conventional treatment in patients with schizophrenia.

Medical condition

schizophrenia

Phase

Phase 4

Healthy volunteers

No

Study drug

Quetiapine fumarate, conventional treatment for schizophrenia

Sex

All

Actual Enrollment

85

Study type

Interventional

Age

18 Years - 64 Years

Date

Study Start Date: 01 Sept 2005
Primary Completion Date: 01 Dec 2007
Study Completion Date: 01 Dec 2007

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria